WO2008029031A3 - Test pharmaco diagnostique ciblant l' oncologie - Google Patents

Test pharmaco diagnostique ciblant l' oncologie Download PDF

Info

Publication number
WO2008029031A3
WO2008029031A3 PCT/FR2007/001449 FR2007001449W WO2008029031A3 WO 2008029031 A3 WO2008029031 A3 WO 2008029031A3 FR 2007001449 W FR2007001449 W FR 2007001449W WO 2008029031 A3 WO2008029031 A3 WO 2008029031A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
liv21
complex
liv21 complex
extract
Prior art date
Application number
PCT/FR2007/001449
Other languages
English (en)
Other versions
WO2008029031A9 (fr
WO2008029031A2 (fr
WO2008029031A8 (fr
Inventor
Laurence Faure
Original Assignee
Laurence Faure
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laurence Faure filed Critical Laurence Faure
Priority to EP07823487A priority Critical patent/EP2066806A2/fr
Priority to US12/282,117 priority patent/US8314221B2/en
Publication of WO2008029031A2 publication Critical patent/WO2008029031A2/fr
Publication of WO2008029031A3 publication Critical patent/WO2008029031A3/fr
Publication of WO2008029031A9 publication Critical patent/WO2008029031A9/fr
Publication of WO2008029031A8 publication Critical patent/WO2008029031A8/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G01N33/6851—Methods of protein analysis involving laser desorption ionisation mass spectrometry

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Hospice & Palliative Care (AREA)
  • Optics & Photonics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)

Abstract

Un premier objectif de la présente invention est de mettre en évidence une méthode de détection et de pronostic du cancer et de son potentiel métastatique. De préférence, le cancer est sélectionné parmi les cancers du sein, de la vessie, de l'ovaire, du poumon, de la peau, de la prostate, du colon, du foie, un sarcome, une leucémie sans être limité à ceux-ci. Un aspect de la présente invention consiste en l'utilisation du complexe LIV21 comme indicateur pronostic du cancer et dans son suivi thérapeutique. On définit le complexe LIV21 par l'extrait de protéines et peptides étudiés en spectrométrie de masse type Maldi et ESI MSMS ou Maldi Tof Tof. Lequel extrait a été obtenu par l'accrochage du complexe Liv21 à un de ces anticorps polyclonaux de LIV21. Le complexe Liv21 se définit aussi par son profil global de spectrométrie de masse (Fig 5) et le nombre et le Poids moléculaire des bandes d'extraits protéiques obtenus fonction de la température à laquelle est soumis l'échantillon et des conditions de migration décrites. Un autre aspect est l'utilisation de biopuces pour le pharmaco diagnostic des pathologies de Poncologie et de la neurodégénérescence.
PCT/FR2007/001449 2006-09-07 2007-09-07 Test pharmaco diagnostique ciblant l' oncologie WO2008029031A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP07823487A EP2066806A2 (fr) 2006-09-07 2007-09-07 Test pharmaco diagnostique ciblant l'oncologie
US12/282,117 US8314221B2 (en) 2006-09-07 2007-09-07 Pharmacodiagnostic test targeting oncology and neurodegeneration

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0607859 2006-09-07
FR0607859 2006-09-07

Publications (4)

Publication Number Publication Date
WO2008029031A2 WO2008029031A2 (fr) 2008-03-13
WO2008029031A3 true WO2008029031A3 (fr) 2008-11-13
WO2008029031A9 WO2008029031A9 (fr) 2009-01-08
WO2008029031A8 WO2008029031A8 (fr) 2009-07-16

Family

ID=38265552

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2007/001449 WO2008029031A2 (fr) 2006-09-07 2007-09-07 Test pharmaco diagnostique ciblant l' oncologie

Country Status (3)

Country Link
US (1) US8314221B2 (fr)
EP (1) EP2066806A2 (fr)
WO (1) WO2008029031A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5564249B2 (ja) * 2006-06-23 2014-07-30 アレシア・バイオセラピューティクス・インコーポレーテッド 癌に関与するポリヌクレオチド配列およびポリペプチド配列
WO2012127124A1 (fr) * 2011-03-18 2012-09-27 Laurence Faure Tests dedies a l'oncologie et a la neuro oncologie
US20130324478A1 (en) 2008-09-08 2013-12-05 Laurence Faure Pharmacodiagnosis Test Targeting Oncology and Neurodegeneration
EP2362908A4 (fr) 2008-11-03 2013-09-18 Alethia Biotherapeutics Inc Anticorps qui bloquent spécifiquement l'activité biologique d'un antigène tumoral
FR2950075A1 (fr) * 2009-09-17 2011-03-18 Laurence Faure Test pharmaco diagnostic ciblant l'oncologie: cancers epidermoides
FR2950076A1 (fr) * 2009-09-17 2011-03-18 Laurence Faure Test pharmaco diagnostic ciblant la neuro oncologie et la maladie d'alzheimer
CN101963617B (zh) * 2010-05-26 2013-07-10 江西中烟工业有限责任公司 测定体液中尼古丁的新型间接抑制免疫分析法
CA2888908A1 (fr) 2011-03-31 2012-10-04 Alethia Biotherapeutics Inc. Anticorps contre l'antigene 1 associe aux reins et leurs fragments de liaison a l'antigene
JP6282597B2 (ja) 2012-01-09 2018-02-21 アー・デー・ツェー・セラピューティクス・エス・アー 乳癌を治療する方法
KR101511737B1 (ko) * 2012-12-31 2015-04-20 대한민국 Sumo1 및 bace1의 결합 억제제를 유효성분으로 함유하는 퇴행성 뇌질환 예방 및 치료용 약학적 조성물
WO2015196121A2 (fr) * 2014-06-19 2015-12-23 University Of South Florida Méthode de traitement d'un cancer de l'ovaire à l'aide d'un inhibiteur de pkc

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001064736A2 (fr) * 2000-03-03 2001-09-07 Institut National De La Sante Et De La Recherche Medicale (I.N.S.E.R.M.) Nouveaux composes servant a reguler la proliferation et/ou la differenciation de cellules, et applications biologiques associees
WO2006095086A2 (fr) * 2005-03-07 2006-09-14 Laurence Faure Traçabilite des anomalies du cycle cellulaire ciblant l'oncologie et la neurodegenerescence.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474796A (en) * 1991-09-04 1995-12-12 Protogene Laboratories, Inc. Method and apparatus for conducting an array of chemical reactions on a support surface
US20030027139A1 (en) * 2000-04-06 2003-02-06 Kenneth Jacobs Polynucleotides encoding novel secreted proteins
WO2002030966A2 (fr) * 2000-10-06 2002-04-18 Incyte Genomics, Inc. Proteines associees a la maladie d'alzheimer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001064736A2 (fr) * 2000-03-03 2001-09-07 Institut National De La Sante Et De La Recherche Medicale (I.N.S.E.R.M.) Nouveaux composes servant a reguler la proliferation et/ou la differenciation de cellules, et applications biologiques associees
WO2006095086A2 (fr) * 2005-03-07 2006-09-14 Laurence Faure Traçabilite des anomalies du cycle cellulaire ciblant l'oncologie et la neurodegenerescence.

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
"AFFYMETRIX CATALOG", AFFYMETRIX PRODUCT CATALOG, July 2002 (2002-07-01), pages 1, XP002267612 *
"Human Genome U95 Set", ANNOUNCEMENT AFFYMETRIX, April 2000 (2000-04-01), pages 1 - 2, XP002284454 *
AHNEN D J: "Tissue markers of colon cancer risk", GASTROINTESTINAL ENDOSCOPY, ELSEVIER, NL, vol. 49, no. 3 Pt 2, 1 March 1999 (1999-03-01), pages S50 - S59, XP002374769, ISSN: 0016-5107 *
ALITALO K ET AL: "Human BEC/LEC-related protein sequence SeqID129", GENESEQ, 1 July 2004 (2004-07-01), XP002402779 *
ASHOUR AHMED A ET AL: "Microarrays and breast cancer clinical studies: Forgetting what we have not yet learnt", BREAST CANCER RESEARCH, CURRENT SCIENCE, LONDON, GB, vol. 7, no. 3, 1 May 2005 (2005-05-01), pages 96 - 99, XP002472524, ISSN: 1465-5411 *
CHANG J C ET AL: "Genomic approaches in the management and treatment of breast cancer", BRITISH JOURNAL OF CANCER, LONDON, GB, vol. 92, no. 4, 28 February 2005 (2005-02-28), pages 618 - 624, XP002472525, ISSN: 0007-0920 *
CRISANTI PATRICIA ET AL: "Cloning and characterization of a novel transcription factor involved in cellular proliferation arrest: PATF", ONCOGENE, BASINGSTOKE, HANTS, GB, vol. 20, no. 39, 6 September 2001 (2001-09-06), pages 5475 - 5483, XP000926674, ISSN: 0950-9232 *
DATABASE Geneseq [online] 6 May 2004 (2004-05-06), "Novel human polypeptide SeqID8519.", XP002489652, retrieved from EBI accession no. GSP:ADK36437 Database accession no. ADK36437 *
DATABASE Geneseq [online] 8 May 2002 (2002-05-08), "cDNA sequence #460 encoding novel human secreted protein.", XP002489651, retrieved from EBI accession no. GSN:ABK36069 Database accession no. ABK36069 *
GAO X ET AL: "DIAGNOSTIC AND PROGNOSTIC MARKERS FOR HUMAN PROSTATE CANCER", PROSTATE, WILEY-LISS, NEW YORK, NY, US, vol. 31, no. 4, 1 January 1997 (1997-01-01), pages 264 - 281, XP000998020, ISSN: 0270-4137 *
KNAUF J A ET AL: "Involvement of protein kinase Cepsilon (PKCepsilon) in thyroid cell death. A truncated chimeric PKCepsilon cloned from a thyroid cancer cell line protects thyroid cells from apoptosis", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, vol. 274, no. 33, 13 August 1999 (1999-08-13), pages 23414 - 23425, XP002402849, ISSN: 0021-9258 *
SUN YIJUN ET AL: "Improved breast cancer prognosis through the combination of clinical and genetic markers", BIOINFORMATICS, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 23, no. 1, 1 January 2007 (2007-01-01), pages 30 - 37, XP002472523, ISSN: 1367-4803 *

Also Published As

Publication number Publication date
US20090311681A1 (en) 2009-12-17
EP2066806A2 (fr) 2009-06-10
WO2008029031A9 (fr) 2009-01-08
US8314221B2 (en) 2012-11-20
WO2008029031A2 (fr) 2008-03-13
WO2008029031A8 (fr) 2009-07-16

Similar Documents

Publication Publication Date Title
WO2008029031A8 (fr) Test pharmaco diagnostique ciblant l' oncologie
Megger et al. Comparison of label-free and label-based strategies for proteome analysis of hepatoma cell lines
CA2844033C (fr) Procede de detection du cancer du pancreas
TWI317811B (fr)
Jou et al. S100A8 as potential salivary biomarker of oral squamous cell carcinoma using nanoLC–MS/MS
WO2004076679A3 (fr) Facteur d'inhibition de la migration des macrophages (mif) serique servant de marqueur pour le cancer de la prostate
WO2003021273A3 (fr) Diagnostic de carcinomes
WO2006133923A3 (fr) Diagnostic, pronostic, et prediction de la recurrence des cancers du sein
EP2177614A3 (fr) Composition et procédé permettant de diagnostiquer un cancer oesophagien et une métastase d'un cancer oesophagien
WO2007095644A3 (fr) reactifs et procedes pour le pronostic et la stadification pathologique d'un cancer
WO2007035690A3 (fr) Methodes de diagnostic du cancer du pancreas
Xiao et al. Quantitative proteomic analysis of microdissected oral epithelium for cancer biomarker discovery
Chow et al. Analysis of protein profiles in human epithelial ovarian cancer tissues by proteomic technology.
Wang et al. Differential N-glycan patterns identified in lung adenocarcinoma by N-glycan profiling of formalin-fixed paraffin-embedded (FFPE) tissue sections
WO2006091421A3 (fr) Peptides pour la detection d'un anticorps dirige contre ehrlichia ewingii
Park et al. Subunit-specific mass spectrometry method identifies haptoglobin subunit alpha as a diagnostic marker in non-small cell lung cancer
RU2016116773A (ru) Способ выявления опухоли поджелудочной железы, антитела и набор для выявления опухоли поджелудочной железы
WO2008054724A3 (fr) Anticorps monoclonaux contre l'ostéopontine
WO2015077382A3 (fr) Test cytologique et moléculaire combiné pour la détection précoce d'adénocarcinome œsophagien
WO2007020522A3 (fr) Marqueurs proteiniques permettant de diagnostiquer un cancer colorectal et utilisation de ces marqueurs comme cibles de medicament en vue du traitement de ce type de cancer
Xu et al. The next “sweet” spot for pancreatic ductal adenocarcinoma: Glycoprotein for early detection
WO2008131261A3 (fr) Biomarqueurs peptidiques de maladie cardiovasculaire
WO2007087263A3 (fr) Citrate, zinc et zip1 humain destines au criblage d’un cancer de la prostate
WO2018013678A3 (fr) Marqueurs moléculaires et procédés d'analyse d'échantillons par spectrométrie de masse
WO2009019369A3 (fr) Procede de dosage de la plastine-i pour le diagnostic in vitro du cancer colorectal

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07823487

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 12282117

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007823487

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2239/DELNP/2009

Country of ref document: IN